Document:

Exhibit
10.1

 

Management
Services Agreement

 

THIS
MANAGEMENT SERVICES AGREEMENT (this “Agreement”), dated as of February 25, 2022 (the “Effective Date”)
is entered into by and between ResearchDx, Inc., a California corporation, (“Consultant”) and LucidDx Labs Inc., a
Delaware corporation (“Company”). Consultant and Company are sometimes referred to herein individually as a “Party”
and collectively as the “Parties” to this Agreement.

 

RECITALS:

 

WHEREAS,
Company owns and operates a CLIA-certified high-complexity, laboratory located at 14 Orchard Road, Lake Forest, CA 92630 (the “Laboratory”);
and

 

WHEREAS,
Consultant possesses such expertise, and Company desires to retain Consultant, to provide general management and operations of the Laboratory,
including, but not limited to, providing a qualified laboratory director and laboratory personnel, as may be necessary under the terms
and conditions set forth in this Agreement.

 

NOW,
THEREFORE, in consideration of the recitals, mutual promises, covenants and other valuable consideration contained in this Agreement,
the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:

 

Article
I

SCOPE
OF SERVICES; CONSULTANT’s RESPONSIBILITIES

 

(a)
From and after the Effective Date, Consultant shall provide the following services to Company and the Laboratory (subject to the right
of Company, in its sole discretion, to elect to terminate any portion of such services in accordance with Article V(a), whether due to
its determination to render such services with its own personnel or otherwise) (collectively, the “Services”):

 

(1)
Laboratory Director. Consultant shall provide either (i) two laboratory directors, one of which is licensed to practice medicine
without restriction in the State of California, and the other of which holds a certificate of qualification in generic testing/molecular
oncology in the State of New York, or (ii) one laboratory director who meets both criteria set forth in the previous clause (i) (such
laboratory director(s), the “Laboratory Director(s)”) each of whom will be licensed and qualified, and shall remain
in good standing with, all applicable federal and state laws, including, without limit, the federal Clinical Laboratory Improvement Amendments
and its implementing regulations (“CLIA”); the State of California’s Business and Professions Code and/or the
applicable state laboratory laws and rules in the state of New York, as applicable; the Laboratory’s accrediting bodies (if applicable)
(collectively, the “Laboratory Rules”). The Laboratory Directors shall be responsible for performing, or arranging
for or delegating as permitted, all the duties and responsibilities required under the Laboratory Rules (the “Laboratory Director
Services”). Each Laboratory Director will assist the Laboratory in maintaining compliance with all applicable federal and state
laws, rules, regulations, standards and ordinances, and judicial and administrative interpretations thereof, all criteria and standards
of applicable accreditation agencies of Laboratory, and all other policies and procedures duly established by Company and the Laboratory,
including, without limit, the services and activities set forth in Exhibit A attached hereto. At all times during the term
of this Agreement, Laboratory Director will meet all of the qualifications (“Laboratory Director Qualifications”)
as follows:

 

    	Exhibit A-1

     

    

 

(i)
Licensed to practice medicine without restriction in the State of California or the State of New York, as applicable;

 

(ii)
Eligible and compliant with all criteria for laboratory director of a high complexity laboratory under the Laboratory Rules;

 

(iii)
Eligible to enroll and participate in any federal and state government health care programs; and

 

(iv)
Compliant with (a) the policies and procedures of Company and the Laboratory and (b) the requirements of various governmental and accrediting
agencies applicable to Laboratory, as may be amended from time to time.

 

As
used herein, references to “Laboratory Director” shall mean the laboratory director licensed to practice medicine without
restriction in the State of California, or the laboratory director holding a certificate of qualification in generic testing/molecular
oncology in the State of New York, as the context may require.

 

(2)
Laboratory Operations. Consultant, together with the Laboratory Director, shall manage and oversee all of the Laboratory’s
clinical and operational activities, including, without limit, ensuring that: (i) the Laboratory’s testing systems are appropriate
and provide quality services in all aspects of test performance (i.e., pre-analytic, analytic, and post-analytic phases of testing);
(ii) the Laboratory’s physical and environmental conditions are adequate and appropriate for the testing performed; (iii) the environment
for personnel is safe from physical, chemical, and biological hazards and that biohazard and safety requirements are followed; (iv) a
general supervisor for high complexity testing is available to provide day-to-day supervision of all testing personnel and reporting
of test results while providing on-site supervision for specific minimally qualified testing personnel when performing such high complexity
testing; (v) sufficient numbers of appropriately qualified Laboratory Personnel (defined below) are employed at the Laboratory; (vi)
new assay procedures are reviewed, included in the appropriate procedure manual, and followed by Technical Personnel (defined below);
(vii) all assays are appropriately performed in accordance with Consultant and Company’s procedures and a weekly testing schedule
to be agreed upon by the Parties (which schedules shall be designed, to the extent practicable, to maximize the efficiency of the performance
of the Test Services (as defined below)); and (viii) if requested by Company, all Laboratory Personnel’s responsibilities and duties
are specified in written standard operating procedures. Consultant shall provide training of the Technical Personnel on all methods and
procedures of all tests performed by the Laboratory, including, without limit, the EsoGuard assay (collectively, the “Test Services”),
as well as provide ongoing support to the Laboratory Personnel, as needed. Consultant will periodically monitor quality and efficiency
and conduct periodic reviews to make recommendations to Company relating to the Test Services.

 

(3)
Laboratory Personnel. Consultant shall hire or retain the services of all Laboratory Personnel necessary to perform the Services
under this Agreement, as may fluctuate from time to time, that are educated, experienced, and trained to accurately perform tests and
report test results in the Laboratory, each of whom shall be licensed and qualified as required under the Laboratory Rules. All Laboratory
Personnel shall be employees or agents of Consultant and shall be directly compensated by Consultant. All Laboratory Personnel shall
perform their duties under the oversight and management of the Laboratory Director. All personnel decisions, including, but not limited
to, those regarding the employment, retention, promotion, and termination of Laboratory Personnel, may be made by Consultant. If Company
determines that it is not satisfied with the performance hereunder of any individual that is part of the Laboratory Personnel, Consultant
shall upon request by Company use commercially reasonable efforts to replace such individual with someone satisfactory to Company Consultant
shall ensure that all Laboratory Personnel involved in the performance of services hereunder have executed a written agreement, in form
and substance reasonably acceptable to Company, that binds such personnel to confidentiality provisions that are at least as protective
of Confidential Information of Company as those contained in this Agreement and, upon Company’s request, provide Company with a
copy of each such executed agreement. Company agrees that no Laboratory Personnel shall be considered an employee of Company or entitled
to any benefits or eligible for participation in any benefits plans provided to employees of Company. Consultant further agrees to indemnify
and hold harmless Company and its affiliates against any and all liability for claims by Laboratory Personnel asserting an employment
relationship with Company or its affiliates in connection with the Services performed hereunder. For the purposes of this Agreement,
“Laboratory Personnel” means the employees of Consultant who are responsible for management and oversight of the Laboratory
(the “Management Personnel”), and the employees of Consultant who perform the Test Services (the “Technical
Personnel”). A list of all Management Personnel and Technical Personnel in each case that are involved in the performance of
Services as of the date hereof and their respective compensation levels are set forth on Schedule 1(a)(3). Consultant agrees to
provide Company an updated version of such exhibit from time to time (but no less frequently than quarterly) to reflect any changes in
the Management Personnel or Technical Personnel in each case that are involved in the performance of Services or their respective annual
compensation levels.

 

    	Exhibit A-2

     

    

 

(4)
Equipment and Supplies. Consultant shall provide general inventory management services for the Laboratory as required in performing
the Test Services to ensure an adequate level of inventory of the EsoGuard assay is readily available to the Laboratory in light of the
volume of Test Services being performed (and forecasted to be performed) thereat. Consultant shall recommend for purchase or lease by
Company any equipment reasonably necessary to run the Test Services (the “Equipment”) and the consumable supplies
reasonably necessary to perform the Test Services (the “Supplies”). As requested by Company, Consultant shall fulfill
the Laboratory’s need for Equipment and Supplies at the Company’s cost and expense (and provided that Company will reimburse
Consultant for the out-of-pocket cost of any such Equipment and Supplies and any related services within thirty (30) days after receipt
of an invoice therefor); provided that, Company shall have final authority over all decisions relating to the purchase of any such Equipment
and Supplies. Consultant shall be responsible for the maintenance of all Equipment and Supplies in the Laboratory, including the Equipment
and Supplies as may be acquired, unless the foregoing are covered by manufacturer services contracts or warranties. Without duplication
of any other provision hereof and except as otherwise expressly provided herein, Company will be responsible for the purchase of all
Equipment, Supplies and related services, which Consultant may purchase on Company’s behalf or through Company’s account.

 

(5)
Laboratory Vendors. When outside vendors are required for Company to perform the Test Services, Consultant will identify and make
arrangements and coordinate with such vendors. Consultant hereby covenants that it shall conduct exclusion screens and only work with
vendors who are not excluded from Medicare, Medicaid or any other federal health care program (as defined in 42 U.S.C. § 1320a-7b(f))
(“FHCP”).

 

(6)
Certification; Compliance. Company will assist Consultant in, and the clerical tasks involved with, completing the necessary forms
and facilitating the process for the Laboratory to obtain and maintain any certifications, accreditations, permits or licenses that are
required for Company to perform the Test Services. Consultant will provide on-site support for pre-scheduled CLIA and other regulatory
inspections. Consultant and Laboratory Director together with the Company will determine, compile, and draft any required corrective
actions for any deficiencies in connection therewith or related to any compliant inspection.

 

    	Exhibit A-3

     

    

 

(7)
No Marketing. Consultant shall not be responsible for, and will not undertake any, marketing of Company’s Test Services,
including, without limit, no solicitation, promotion, arranging for, or recommending of the purchase of Company’s Test Services.

 

(b)
IT Systems. Consultant shall assist Company in securing all information technology related equipment, including, without limitation,
all necessary computer equipment, hardware, software, laboratory information system software, connectivity devices, and technology services
and the service contracts for the same to operate the Laboratory (collectively, the “IT System”). Consultant agrees
to, as directed by Company, to upload and maintain any and all documentation and other written materials generated by Consultant in connection
herewith to a directory residing on the IT System that is dedicated to the services to be rendered hereunder. To facilitate the foregoing,
Company shall provide Consultant with read/write access during the Term to the applicable directory and any instructions for uploading
and maintaining such documentation and written materials within the same. In addition to the foregoing, Consultant shall utilize Company’s
IT System for the sole purpose of performing the Services under this Agreement. Consultant shall: (1) never access or use the IT System
for any purposes except as expressly permitted hereunder; and (2) use the IT System in accordance with the terms and conditions of any
license agreement entered into by and between Company and any vendor or owner of such IT System and any and all Specifications. For the
purposes of this Agreement, “Specifications” means: (i) system flow charts, program descriptions, file layouts, database
structures, report layouts and screen layouts, interface requirements and layouts, conversion requirements and layouts, refined equipment
requirements, acceptance criteria and acceptance test scripts for improvements, enhancements or other alterations required in connection
with any of the IT System; and (ii) all operator and user manuals, training materials, guides, listings, specifications and other materials
necessary for the complete understanding and use of the functionality of any of the IT System.

 

(c)
Reports and Records.

 

(1)
Consultant, in coordination with Laboratory Director, will prepare and maintain, or cause to be prepared and maintained, and provide
to Company such information and documentation that Company may require from time to time in order for the Laboratory to secure reimbursement
from federal or state agencies, intermediaries, carriers, other third-party payors, or patients for services provided at the Laboratory.
Such information may include, but not be limited to, the recording and maintenance by Laboratory Director of time records required by
any FHCP or any third-party payor of all services provided by Laboratory Director. The Parties agree that any records prepared and maintained
under this Section will be the property of Company and Consultant’s obligation to return such records will survive the termination
of this Agreement.

 

(2)
Consultant will assist the Company in maintaining all Laboratory records and materials, including, but not limited to, all test requisitions
and reports, staff files, and data and documentation obtained or generated by Consultant in preparing for or providing the Services hereunder,
including all computerized records and files (collectively, the “Records”) in a secure area reasonably protected from
fire, theft and destruction. Company will provide an onsite location reasonably protected from fire, theft and destruction, where such
Records shall be maintained. Consultant may retain copies of any Records as are reasonably necessary for regulatory or insurance purposes,
subject to Consultant’s obligations of confidentiality under this Agreement. Consultant will not dispose of any Records, except
as directed by Company

 

(d)
Consultant shall make every effort to retain test samples on behalf of Company for a reasonable period depending on the amount of sample
received and used in the testing process and as required under applicable law or regulation. In any event, Consultant will ensure that
samples, to the extent in its custody during the term of this Agreement, are stored at the Laboratory and maintained in accordance with
the Laboratory specimen retention standard operating procedures, as in effect from time to time.

 

    	Exhibit A-4

     

    

 

(e)
Consultant shall perform all Services with reasonable care, in accordance with generally accepted practices in the clinical laboratory
industry and in accordance and compliance with applicable federal, state, and local laws and regulations and any applicable accrediting
standards.

 

Article
II

COMPANY’s
RESPONSIBILITIES

 

(a)
Notwithstanding anything to the contrary contained herein, the ultimate control of the Laboratory shall remain at all times with Company,
and Company, by entering into this Agreement, delegates to Consultant only those certain limited powers, duties, and responsibilities
expressly set forth in this Agreement. Company shall retain the ultimate responsibility for the Laboratory’s compliance with all
applicable laws and regulations, including, without limit, the Laboratory Rules.

 

(b)
Unless otherwise required herein, or by applicable law, Company shall own and/or hold all certifications, accreditations, permits or
licenses with respect to the Laboratory, and shall be the “provider” within the meaning of all third-party contracts for
the Test Services. To be certain, any fees for such certifications, accreditations, permits, or licenses of the Laboratory shall be paid
by the Company.

 

(c)
Company shall retain sole authority with respect to the establishment of fees or charges for provision of the Test Services at the Laboratory.

 

Article
III

COMPENSATION

 

(a)
Minimum Quarterly Payment: Subject to the terms of this Agreement, the base compensation to be paid to Consultant for the Services
rendered shall be One Million Eight Hundred Thousand Dollars ($1,800,000.00) payable in quarterly payments of One Hundred Fifty Thousand
Dollars ($150,000.00) (“Minimum Quarterly Payment”) during the Initial Term. Each Minimum Quarterly Payment will be
paid by the fifteenth (15th) day following the expiration of each applicable three (3)-month quarterly period during the Initial
Term. The Minimum Quarterly Payment under this Article III(a) shall be payable only if and while this Agreement is effective.
In the event of the termination or expiration hereof, the payment obligations under this Article III(a) shall become null and
void and commencing on such effective date of termination (x) Company shall have no obligation whatsoever to make any further Minimum
Quarterly Payments, and (y) Consultant shall have no right, title, or interest whatsoever in any further Minimum Quarterly Payments,
provided that if the effective date of such termination occurs during any three (3)-month quarterly period, Company shall pay to Consultant
an amount equal to the ratable portion of the Minimum Quarterly Payment in respect of that partial period. For the abundance of clarity,
except as provided in the proviso of the prior sentence, Company shall not be required to pay to Consultant any unpaid Minimum Quarterly
Payments if Company terminates this Agreement with or without cause. For avoidance of doubt, the Parties hereby acknowledge and agree
that the Minimum Quarterly Payment due and owing hereunder is without duplication of the same described in that certain Asset Purchase
Agreement, dated as of the date hereof, by and between Company and Consultant (“Purchase Agreement”). 

 

(b)
Personnel Fee: A monthly fee, to initially equal the amount set forth in Schedule 1(a)(3) (as the same may be adjusted from time
to time pursuant to Article III(f) below, the “Personnel Fee”) shall be paid to Consultant, which fee is intended,
without markup, to cover the compensation expenses in respect of Laboratory Personnel incurred by Consultant that are properly allocable
to Consultant’s management of the operations of the Laboratory, data entry tasks, IT support, quality control management, EsoGuard
assay performance, Equipment and Supplies maintenance not covered by manufacturer services contracts and the Test Services.  

 

    	Exhibit A-5

     

    

 

(c)
Invoice: Company shall be invoiced by Consultant for the Personnel Fee on or after the first (1st) day of each month, and all
undisputed invoice amounts shall be due within thirty (30) days following Company’s receipt of such invoice.

 

(d)
With regards to the Personnel Fee, as noted above, such fees are intended to cover the actual and documented expenses, in each case without
markup, incurred by Consultant that are properly allocable to the provision of the applicable associated services. To ensure that such
fees will cover (and will only cover) such expenses without markup, the Parties shall, on a quarterly basis (or at such other times as
mutually agreed in by the Parties), review and agree in good faith to adjust such fees to reflect any changes in Consultant’s expenses
incurred in connection with the provision of the applicable services since the last adjustment to fees made hereunder, including those
changes resulting from Consultant’s cost structuring or insourcing of any applicable services to Company’s own personnel
or any other termination of a portion of the Services by Company in accordance with Article V(a) below. To the extent any Consultant
personnel or other resources are devoted to the performance of services for Company and other Consultant clients, in determining any
adjustments to the Personnel Fee pursuant to the foregoing, the portion of the costs associated with such shared personnel or other resources
to be covered by the Personnel Fee shall be determined based on the actual compensation levels of such personnel, the actual out-of-pocket
cost to Consultant of such other resources and the amount of time such personnel or resources were devoted to the performance of the
associated services hereunder as a percentage of the total time such personnel and resources devote to performance of services on behalf
of Consultant, whether for the benefit of Customer or other Consultant clients. No amount to be paid hereunder is intended to be, nor
shall it be construed to be, an inducement or payment by Company for referral of patients by Consultant or any of its affiliates.

 

(e)
During the Term and for twelve months after the termination hereof, Consultant shall maintain complete and accurate books and records
regarding the calculation of fees due and payable hereunder. In addition, during the Term and for twelve months after the termination
hereof, upon Company’s reasonable request, Consultant shall make such books and records, and appropriate personnel, available during
normal business hours for inspection or audit by Company or its authorized representative, provided that Company shall conduct or cause
to be conducted such audit in a manner designed to minimize disruption of Consultant’s normal business operations. Consultant shall
immediately upon notice from Company pay Company the undisputed amount of any overpayment revealed by any audit and Company shall immediately
upon notice from Consultant pay Consultant the undisputed amount of any underpayment revealed in any audit.

 

Article
IV

TERM

 

(a)
This Agreement shall commence on the Effective Date and shall continue thereafter for three (3) years (the “Initial Term”)
unless or this Agreement is terminated pursuant to Article V.

 

Article
V

TERMINATION

 

(a)
Without Cause Termination. Company may terminate this Agreement (or any portion of the Services to be provided hereunder) without
cause upon thirty (30) days prior notice to Consultant. In the event of any termination of a portion of the Services to be provided hereunder,
this Agreement shall only terminate with respect to such terminated Services, and the balance of this Agreement shall remain in full
force and effect. 

 

    	Exhibit A-6

     

    

 

(b)
With Cause Termination. Either Party may terminate this Agreement upon the occurrence of any one or more of the following events:

 

(1)
The material breach of this Agreement by the other Party without cure within thirty (30) days of receiving the non-breaching Party’s
written notice of such breach;

 

(2)
Immediately, by the non-breaching Party, upon the other Party’s: (i) insolvency; (ii) appointing of a receiver for any part of
such Party’s property; (iii) assignment for the benefit of such Party’s creditors; or (iv) commencement of any proceedings
under any bankruptcy or insolvency law by or against such Party that is not dismissed within sixty (60) days after the filing of such
proceeding; and

 

(3)
Immediately if: (i) the other Party fails to comply in all respects with any applicable Law; (ii) the other Party, or any of its Representatives
(defined below), is excluded from participation in any FHCP; or (iii) (x) any governmental entity enacts, adopts, or amends a law, rule,
or regulation, (y) if any governmental entity or court of competent jurisdiction adopts or amends an interpretation of a law, or (z)
if a judgment or award is rendered in litigation that has the effect of prohibiting any right or obligation of the Parties under this
Agreement.

 

(c)
Effect of Termination. Upon any termination in full or expiration of this Agreement, for any reason, all rights, covenants and
obligations of the Parties and any authorization of Consultant to act on behalf of Company granted by Company hereunder shall cease,
except for those rights, covenants, and obligations that have accrued or expressly survive such termination or expiration. Upon notice
of termination, both Parties shall use best efforts to cancel any financial obligations incurred and shall avoid incurring any additional
costs in connection with the Agreement. Consultant shall be compensated only for the Services actually performed through the effective
date of termination. Promptly upon termination, Consultant agrees to promptly, but in any event within ten (10) business days of termination,
provide such Confidential Information of Company and other information, documentation, digital or hard assets, property or materials
related to work for Company conducted by Consultant under this Agreement that is in Consultant’s possession at such time, subject
to Consultant’s right to retain copies of any such information as required by applicable law or its customary record retention
policy. 

Article
VI

INSURANCE

 

(a)
At all times during the Term, Consultant shall provide and maintain comprehensive general liability and property insurance. This includes
general commercial liability insurance, with minimum limits of $2,000,000 per occurrence and $4,000,000 in the aggregate with respect
to personal injury, bodily injury and property damage insurance, and product liability insurance with minimum limits of $5,000,000 per
occurrence and $5,000,000 in the aggregate. Consultant shall provide proof of such insurance at the Company’s request, in a form
reasonably satisfactory to the Company.

 

(b)
At all times during the Term, Company shall provide and maintain comprehensive liability and errors and omissions insurance suitable
for a CLIA Clinical Laboratory covering the Management Personnel and Technical Personnel in respect of the Services provided hereunder.
Company shall provide proof of such insurance at the Consultants’ request, in a form satisfactory to the Consultant.

 

    	Exhibit A-7

     

    

 

Article
VII

REPRESENTATIONS,
WARRANTIES and other covenants

 

(a)
Consultant represents and warrants that it is eligible to participate in any FHCP, and neither it, nor any of its control persons (as
defined in 42 U.S.C. § 1320a-3a), employees, or agents, in each case who will perform the Services hereunder (which will result
in Company’s submission of claims to a FHCP, private health benefits plan, or commercial insurer): (1) is currently under investigation
for any violation of the various provisions of laws governing any federally funded health care benefit program and/or any private health
care benefit program which would reasonably be expected to lead to exclusion from such programs; (2) is currently debarred, excluded,
suspended or otherwise ineligible to participate in any FHCP or in federal procurement and non-procurement programs; (3) has been convicted
of, (i) a criminal offense within the ambit of 42 U.S.C. §1320a-7(a), the False Claims Act, or any similar federal or state health
care fraud, abuse, or false claims statute but has not yet been excluded, debarred, suspended, or otherwise declared ineligible for participation
in the FHCPs, (ii) a criminal offense relating to neglect or abuse of patients in connection with the delivery of a health care item
or service; (iii) fraud, theft, embezzlement, or other financial misconduct in connection with the delivery of a health care item or
service; (iv) obstructing an investigation or any other crime referred to in (i) or (iii) above, or (v) the unlawful manufacture, distribution,
prescription, or dispensing of a controlled substance; or (4) has been required to pay any civil monetary penalty regarding false, fraudulent,
or impermissible claims under, or payments to induce a reduction of limitation of health care services to beneficiaries of, any FHCP,
private health benefits plan, or commercial insurer.

 

(b)
Consultant represents and warrants that it has no direct or indirect ownership or controlling interest (as defined in Section 1124(a)(3)
of the Social Security Act or any regulations promulgated thereunder) of five percent (5%) or more, and is not an officer, director,
manager, agent or managing employee (as defined in 42 C.F.R. Part 1001), in a “sanctioned entity” that has been convicted
of any offense under 42 C.F.R. Parts 1001 through 1004 or that has been terminated or excluded from participation in any Medicare or
Medicaid program nor has Contractor been an officer or managing employee of such an entity.

 

(c)
Consultant represents and covenants that any person rendering the Services hereunder on behalf of Consultant will not offer or give anything
of value in order to induce referrals to Company or do anything to encourage, condone or assist in the ordering or billing of medically
unnecessary services. Consultant shall not provide any entertainment, gifts, or other benefits for any customer/client or prospective
customer/client in violation of applicable law. Consultant shall consult with Company’s principals or legal counsel over any questions
of proper conduct or sales or marketing activities. Consultant shall immediately notify Company of any known or suspected violation of
law or inappropriate conduct by Consultant or any person rendering the Services hereunder.

 

(d)
Consultant represents and warrants that it is not bound by any other agreement which could prevent, or be violated by, or under which
there would be a default as a result of, the execution and performance of this Agreement, and that Consultant will not enter into any
such conflicting agreements during the term of this Agreement.

 

(e)
Company agrees that during the Term and for 12 months thereafter (the “Restricted Period”), Company will not directly
or indirectly, for its own account or for the account of others, hire, urge, induce, entice, or in any manner whatsoever solicit a Laboratory
Director to leave the employment of Consultant or any of its affiliates. Company agrees that during the Restricted Period, Company will
not directly or indirectly, for its own account or for the account of others, hire, urge, induce, entice, or in any manner whatsoever
solicit any Consultant employee other than a Laboratory Director to leave the employment of Consultant or any of its affiliates without
first discussing such solicitation or hiring with the Consultant. Subject to the foregoing requirement to so discuss such solicitation
or hiring, Company agrees that if during the Restricted Period, any Consultant employee other than a Laboratory Director leaves the employment
of Consultant and becomes an employee of Company or any of Company’s affiliates, Company will pay Consultant 30% of the employee
actual total compensation for the 12 month period ending on the termination date of such employee’s employment with Consultant.

 

    	Exhibit A-8

     

    

 

Article
VIII

COMPLIANCE

 

(a)
Until the expiration of six (6) years after the furnishing of the Services provided under this Agreement, the Parties agree to make available
to the Secretary of the U.S. Department of Health and Human Services, the U.S. Comptroller General, the Social Security Administration,
and their representatives, this Agreement and all books, documents and records necessary to certify the nature and extent of the costs
of the Services rendered under this Agreement. If the duties of the Agreement are carried out through a subcontract worth $10,000 or
more over a twelve (12) month period with a related organization, the subcontract will also contain an access clause to permit access
by the Secretary, Comptroller General and their representatives to the related organization’s books and records. This clause applies
regardless of whether the Party is designated elsewhere in this Agreement as a contractor, subcontractor, vendor, and seller or otherwise.

 

(b)
The Parties intend at all times to comply fully with all applicable laws concerning the Services contemplated hereunder, including, without
limit, all applicable federal, state and local laws, rules and regulations related to the operation of a CLIA-certified laboratory facility.

 

(c)
The Parties agree to preserve the confidentiality of any patient information exchanged under this Agreement in compliance with all applicable
federal, state and local laws, rules and regulations governing the confidentiality of patient information and medical records (collectively,
“PHI”), including, without limit, the Health Insurance Portability and Accountability Act of 1996, as amended by the
Health Information Technology for Economic and Clinical Health Act and as otherwise may be amended from time to time, and any and all
implementing regulations (collectively “HIPAA”). Contemporaneously with the execution of this Agreement, the Parties
will enter into the HIPAA Business Associate Agreement attached hereto as Exhibit B and incorporated into this Agreement
(the “Business Associate Agreement”), which shall remain in effect during the term of this Agreement.

 

(d)
In the event this Agreement is determined to be legally improper because of any change in the law, including administrative or judicial
interpretations of the law, the Parties shall cooperate in reforming those aspects of this Agreement determined to be legally improper,
while not substantially changing the financial position of any Party, provided that such reformation can be accomplished without the
violation of any applicable rule or regulation.

 

    	Exhibit A-9

     

    

 

Article
IX

INDEMNIFICATION

 

(a)
Company shall defend, indemnify and hold harmless Consultant, its affiliates, and their respective officers, directors, employees, and
agents (collectively, the “Consultant Indemnitees”) from and against any and all liabilities, claims, actions or suits
resulting from any third-party claim made or suit brought against Consultant Indemnitees (“Claims”) arising out of
or relating to: (i) the negligence or willful misconduct of Company, its Affiliates, or their respective employees and agents in connection
with this Agreement, except to the extent caused by or arising out of the negligence or willful misconduct of Consultant Indemnitees;
or (ii) any breach of this Agreement by Company; provided that:

 

(1)
Company must be promptly notified in writing of any Claim within such time as is reasonably necessary to allow Company to respond to
the Claim prior to any legally-required deadline for which indemnification is sought, provided that any failure to so notify Company
shall not limit any of the obligations of Company or any rights of Consultant under this Article IX (except to the extent such failure
materially prejudices the defense of such Claim); and

 

(2)
Company shall have sole control over the defense and settlement of any Claim for which indemnification is sought and the Consultant Indemnitees
shall reasonably cooperate with Company and its representatives in the investigation and defense of the Claim, provided that Company
shall act reasonably and in good faith with respect to the defense or settlement of the Claim as to the Consultant Indemnitees and will
not reach any settlement which does not include an unconditional release of each Consultant Indemnitee from all liabilities and obligations
in connection with such Claim or requires an admission of fault by a Consultant Indemnitee without that Consultant Indemnitee’s
prior written consent.

 

(b)
Consultant shall defend, indemnify and hold harmless Company, its affiliates, and their respective officers, directors, employees, and
agents (collectively, the “Company Indemnitees”) from and against any and all liabilities, claims, actions or suits
resulting from any third-party claim made or suit brought against Company Indemnitees (“Claims”) arising out of or
relating to (i) the negligence or willful misconduct of Consultant, its affiliates, or their respective employees, agents, or subcontractors,
except to the extent caused by or arising out of the negligence or willful misconduct of Company Indemnitees; or (ii) any breach of this
Agreement by Consultant; provided that:

 

(1)
Consultant must be promptly notified in writing of any Claim within such time as is reasonably necessary to allow Consultant to respond
to the Claim prior to any legally-required deadline for which indemnification is sought, provided that any failure to so notify Consultant
shall not limit any of the obligations of Consultant or any of the rights of Company under this Article IX (except to the extent such
failure materially prejudices the defense of such Claim); and

 

(2)
Consultant shall have sole control over the defense and settlement of any Claim for which indemnification is sought and the Company Indemnitees
shall reasonably cooperate with Consultant and its representatives in the investigation and defense of the Claim, provided that Consultant
shall act reasonably and in good faith with respect to the defense or settlement of the Claim as to the Company Indemnitees and will
not reach any settlement which does not include an unconditional release of each Company Indemnitee from all liabilities and obligations
in connection with such Claim or requires an admission of fault by a Company Indemnitee without that Company Indemnitee’s prior
written consent.

 

Article
X

CONFIDENTIALITY

 

(a)
Confidentiality.

 

(1)
The Parties agree that neither Party, nor their respective members, managers, officers, employees, agents, affiliates (collectively,
“Representatives”), or affiliates’ Representatives shall, at any time during the Term or four (4) years after
the date that this Agreement terminates or expires, disclose to anyone any confidential or secret information concerning: (i) the business,
affairs or operation, including any relationship by and between the Parties hereto or with any public or private third-party payor, managed
care company, or commercial insurer; (ii) any trade secrets, new product developments, special or unique processes or methods; or (iii)
any marketing, sales, advertising or other concepts or plans, of the other or any of their respective subsidiaries or affiliates (the
“Confidential Information”). Each of the Parties’ Representatives shall be required to agree to maintain the
Confidential Information in strict confidence and not to disclose any such Confidential Information to any unauthorized person or entity
except to such Party’s employees and other personnel, officers, directors, representations and agents in connection herewith.

 

    	Exhibit A-10

     

    

 

(2)
The Parties hereby acknowledge and agree that this Agreement will be treated as Confidential Information, as that term is defined hereunder
and will be afforded all of the securities as provided for in this Article. Notwithstanding anything to the contrary in this Article
X(a)(2), Company shall have the right to disclose the existence of, and to describe the terms of, this Agreement in any press release
and in any financial or regulatory filings made by it (including attaching this Agreement as an exhibit to any such financial or regulatory
filing, as may be required by applicable law).

 

(3)
This Agreement shall apply to all Confidential Information disclosed by each Party to the other for and during the Term, unless the information
is: (i) in the public domain at the time of disclosure by either Party (other than as a result of a breach of the restrictive covenants
herein), (ii) known to such Party prior to obtaining the same from the other Party, or (iii) obtained by either Party from a third party,
who did not receive the Confidential Information, directly or indirectly, from either Party under a similar confidentiality/nondisclosure
obligation to such Party.

 

(4)
The Parties further acknowledge and agree that they each claim and reserve all rights afforded under all applicable copyright and patent
laws in all Confidential Information furnished hereunder. This Agreement shall not affect any transfer of title in or to any Confidential
Information, and the Parties agree that they shall not assert any right, title, or interest in any Confidential Information of the other.
Each Party acknowledges that it is granted only a limited right to use the Confidential Information of the other Party as aforesaid,
which right terminates upon the expiration or termination of this Agreement, except as required by law.

 

(5)
The restrictions set forth in this Article X shall not apply to disclosure: (i) as expressly authorized by this Agreement; (ii) as required
by law, government regulation, or court order; (iii) with the other Party’s prior written consent; or (iv) to ensure that their
respective employees or agents participating in the performance of this Agreement are advised of the confidential nature of the Confidential
Information and are bound by the terms provided herein. If a Party is requested or required to disclose any Confidential Information
in connection with any legal or administrative proceeding, such Party shall, to the extent not prohibited by law, promptly notify the
other Party in writing of such request or requirement so that the other Party can seek an appropriate protective order or other remedy
to prevent or limit disclosure of the Confidential Information. If such protective order or other remedy is not obtained, such Party
shall furnish only that portion of the Confidential Information that, in the written opinion of such Party’s counsel, is legally
required to be disclosed, and such Party will use its best efforts to obtain assurances that confidential treatment will be accorded
to such information.

 

(6)
The Parties acknowledge that the unauthorized disclosure or use of any Confidential Information could cause irreparable harm and significant
injury which may be difficult to measure with certainty or to compensate through damages. Accordingly, the Parties agree that seeking
injunctive or other equitable relief shall be appropriate without the necessity to post bond in the event of any breach hereof in addition
to such other remedies as may be available at law.

 

(b)
The provisions of this Article X shall survive the expiration or termination of this Agreement as set forth in Article X(a)(1).

 

    	Exhibit A-11

     

    

 

Article
XI

limitation
on liability

 

(a)
EXCEPT WITH RESPECT TO A BREACH OF CONFIDENTIALITY, TO THE EXTENT PERMITTED BY LAW, IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER
FOR COSTS OF PROCUREMENT OF SUBSTITUTE SERVICES, LOST PROFITS, DATA OR BUSINESS, OR FOR ANY SPECIAL, INDIRECT, CONSEQUENTIAL, INCIDENTAL,
EXEMPLARY, OR PUNITIVE DAMAGES INCURRED BY SUCH PARTY ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT (OR THE TERMINATION HEREOF),
HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY (WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE) STRICT LIABILITY OR OTHERWISE, INCLUDING,
BUT NOT LIMITED TO, THE LOSS OF PROSPECTIVE PROFITS OR ANTICIPATED SALES, OR ON ACCOUNT OF EXPENSES, INVESTMENTS, OR COMMITMENTS IN CONNECTION
WITH THE BUSINESS OR GOODWILL OR OTHERWISE. 

 

(b)
EXCEPT WITH RESPECT TO A PARTY’S INDEMNIFICATION OBLIGATIONS OR A BREACH OF CONFIDENTIALITY, EACH PARTY’S TOTAL AND CUMULATIVE
LIABILITY ARISING UNDER OR IN CONNECTION WITH THIS AGREEMENT, WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY OR OTHERWISE,
SHALL IN NO EVENT EXCEED $5,000,000. THE LIMITATIONS SET FORTH IN THIS SECTION SHALL APPLY EVEN IF A PARTY HAS BEEN ADVISED OF THE POSSIBILITY
OF SUCH DAMAGES, AND NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY.

 

Article
XII

MISCELLANEOUS

 

(a)
Party Relationship. For all purposes, the Parties shall be treated as independent contractors and not as, employees, partners
or joint venturers. Without limiting the generality of the preceding sentence, neither Party shall exercise any control over the ownership
or management of the other. Both Parties acknowledge and agree that neither Party shall withhold any amounts for payment of taxes from
the compensation of the other Party’s employees hereunder. As an independent consultant, any and all sums subject to deductions,
if any, required to be withheld and/or paid under any applicable state, federal or municipal laws or union or professional guild regulations
from the compensation of Consultant, shall be Consultant’s sole responsibility and Consultant shall indemnify and hold Company
harmless from any and all damages, claims and expenses arising out of or resulting from any claims asserted by any taxing authority as
a result of or in connection with said payments. This Section shall survive the expiration or termination of this Agreement. 

 

(b)
Waiver. No waiver of any provision hereof shall be valid unless set forth in writing by the Party granting such waiver. If either
Party hereto waives a breach of one of the provisions hereof by the other Party, that waiver shall not operate or be construed as a waiver
of any other provision of this Agreement, or as a waiver of a subsequent similar breach hereof.

 

(c)
Assignment; Subcontract. Neither Party shall assign this Agreement except with the other Party’s prior written consent;
provided, however, such consent, if given, shall not relieve the assigning Party of its representations, warranties, or obligations under
the Agreement. To the extent permitted above, this Agreement shall be binding upon and inure to the benefit of the Parties and their
permitted successors and assigns. 

 

    	Exhibit A-12

     

    

 

(d)
Survival. All provisions which provide that they shall survive the termination of this Agreement or which by their nature are
intended to survive the termination of this Agreement shall so survive. 

 

(e)
Severability. Each section, subsection and lesser section of this Agreement constitutes a separate and distinct undertaking, covenant
and/or provision hereof. In the event that any provision of this Agreement shall finally be determined to be unlawful, such provision
shall be deemed severed from this Agreement, but every other provision of this Agreement shall remain in full force and effect; provided,
however, that upon such determination that any term or other provision is unlawful, the Parties hereto shall modify this Agreement so
as to effect the original intent of the Parties as closely as possible in a legally valid manner in order that each transaction contemplated
hereby is consummated as originally contemplated to the greatest extent possible.  

 

(f)
Governing Law; Dispute Resolution. This Agreement shall be governed by and enforced in accordance with the laws of the State of
New York, without giving effect to principles of conflicts of law. Subject to the last sentence of this paragraph, any dispute or controversy
between the Parties arising out of or relating to this Agreement or the relationship between the Parties shall be submitted exclusively
to arbitration in the City of New York administered by the American Arbitration Association, or alternatively, at the election of Company,
JAMS in dispute. Any decision or award rendered by the arbitrator shall be final and binding on the Parties and shall not be subject
to appeal except as provided by law. Judgment on the award may be enforced in any court of competent jurisdiction. The Parties expressly
authorize the arbitrator to require that all or a portion of the prevailing Party’s fees and expenses (including attorneys’
fees) in the arbitration be allocated to and borne by the other Party, if the arbitrator determines that the other Party’s positions
were sufficiently frivolous so as to make such allocation equitable. The proceedings in arbitration shall be kept confidential. The Parties
irrevocably and unconditionally submit to the exclusive jurisdiction of the Supreme Court of the State of New York, New York County,
and of the United States District Court for the Southern District of New York, for temporary injunctive or other relief in aid of arbitration
or to prevent irreparable harm prior to the appointment of the arbitrator, and irrevocably waive, to the fullest extent they may effectively
do so, the defense of inconvenient forum to the maintenance of any action for any such relief in any such court. 

 

(g)
Notices. All notices, requests, consents, waivers and other communications required or permitted to be given hereunder shall be
in writing or by email and shall be deemed to have been duly given (1) if personally delivered, upon delivery or refusal of delivery,
(2) if mailed by registered or certified United States mail, return receipt requested, postage prepaid, upon delivery or refusal of delivery,
(3) if sent by a nationally recognized overnight delivery service, upon delivery or refusal of delivery, or (4) if sent by email, upon
transmission if during normal business hours on a Business Day or upon the opening of business on the subsequent Business Day if transmitted
after normal business hours. All notices, consents, waivers or other communications required or permitted to be given hereunder shall
be addressed as follows: 

 

If
to the Company:

 

LucidDx
Labs Inc.

One
Grand Central Place, Suite 4600

New
York, NY 10165

Attn:
Lishan Aklog, MD

Phone:
(212) 949-4319

Email:
la@pavmed.com

 

and
a copy to:

 

Friedman
Kaplan Seiler & Adelman LLP

7
Times Square

New
York, NY 10036-6516

Attn:
Michael Gordon, Esq.

Phone:
(212) 833-1197

Email:
mgordon@fklaw.com

 

If
to Consultant:

 

ResearchDx,
Inc.

5
Mason Ln, Suite 100

Irvine,
CA 92618

Attn:
Philip D. Cotter, PhD, FACMGG, FFSc(RCPA)

Phone:
(510) 332-0477

Email:
pcotter@researchdx.com

 

or
at such other address or addresses as the Party addressed may from time to time designate in writing pursuant to notice given in accordance
with this Article XI(g).

 

    	Exhibit A-13

     

    

 

(h)
Headings. The headings in this Agreement are intended solely for convenience of reference and shall be given no effect in the
construction or interpretation of this Agreement. 

 

(i)
Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same Agreement. This Agreement may also be signed and transmitted by facsimile, pdf, or other
electronic means, with such signature to be treated as an original and the document transmitted to be considered to have the same binding
effect as an original signature on an original document. 

 

(j)
Entire Agreement; Amendments. This Agreement sets forth the entire agreement and understanding between the Parties with respect
to the transaction set forth herein, and supersedes all prior agreements, arrangements, understandings and negotiations relating to its
subject matter. This Agreement may be amended, supplemented, or modified only by execution of a written instrument signed by both Parties. 

 

[signature
page follows]

 

    	Exhibit A-14

     

    

 

IN
WITNESS WHEREOF, this Agreement is executed, to be effective as of the Effective Date.

 

	LUCIDDX
    LABS INC.	 	RESEARCHDX,
    INC. 
	 	 	 	 	 
	By:	/s/
    Lishan Aklog, MD	 	By:	/s/
    Philip D. Cotter, PhD
	Name:	Lishan
    Aklog, MD	 	Name:	Philip
    D. Cotter, PhD, FACMGG, FFSc(RCPA)
	Title:	Executive
    Chairman	 	Title:	 

 

[SIGNATURE
PAGE OF Management Services Agreement]Exhibit 4.2

    

    

    DESCRIPTION OF SECURITIES

     

    Under the Amended Certificate of Incorporation (the “Articles”) of Artemis Therapeutics, Inc. (the “Company”), the Company is authorized to issue
      up to fifty-one million (51,000,000) shares of common stock, par value $0.01 per share (the “Common Stock”) and two-hundred thousand (200,000) shares of preferred stock, par value $0.01 per share (the “Preferred Stock”).

     

    The following is a summary of some of the terms of the Company’s Common Stock, which is the Company’s only class of securities registered under
      Section 12 of the Securities Exchange Act of 1934, as amended. The Common Stock is listed on the OTCQB under the symbol “ATMS”. This summary is not complete, and is subject to and qualified by the provisions of the Company’s Articles and the
      Company’s Amended and Restated Bylaws (the “Bylaws”). The terms of the Common Stock are also subject to and qualified by the applicable provisions of the Nevada Revised Statues. Additionally, a summary of some of the terms of the Company’s Preferred
      Stock is provided. This summary is not complete, and is subject to and qualified by the provisions of the Company’s Articles and the Company’s Amended and Restated Bylaws.

     

    Common Stock

     

    The holders of shares of Common Stock vote together as one class on all matters as to which holders of Common Stock are entitled to vote. Except as
      otherwise required by applicable law and subject to the preferential rights of any outstanding Preferred Stock, all voting rights are vested in and exercised by the holders of Common Stock with each share of our Common Stock being entitled to one
      vote, including in all elections of directors. The Company does not have a classified board of directors (the “Board”). Subject to preferences that may be applicable to any outstanding Preferred Stock, the holders of Common Stock are entitled to
      receive ratably such dividends, if any, as may be declared from time to time by the Board out of legally available funds therefore. The Company has not declared any dividends on its Common Stock and does not anticipate paying any dividends on its
      Common Stock in the foreseeable future. In the event of the Company’s liquidation, dissolution or winding up, holders of the Common Stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior liquidation
      rights of Preferred Stock, if any, then outstanding. The Common Stock has no cumulative voting rights and no preemptive or other rights to subscribe for shares of the Company. There are no redemption or sinking fund provisions applicable to the
      Common Stock. All shares of Common Stock currently outstanding are fully paid and non-assessable.

    

    

    Preferred Stock

     

    Pursuant to the Company’s amended Articles, the Company is authorized to issue, up to two-hundred thousand (200,000) shares of preferred stock, par
      value $0.01 per share (the “Preferred Stock”).

     

    There can be one or more series of Preferred Stock. The Company can establish from time to time the number of shares to be included in each such
      series, as well as to fix the designation and any preferences, conversion and other rights and limitations of such series.

     

    To date, the Company has designated four-hundred fifty-three (453) shares of its Preferred Stock as Series A Convertible Preferred Shares, and
      two-hundred  fifty (250) shares of its preferred stock as Series C Convertible Preferred Shares.

    

    

    The Series A Convertible Preferred Shares confer upon their holders the right to receive dividends when paid to holders of common stock of the
      Company on an as-converted basis, and the right to receive a distribution of any surplus of assets upon liquidation of the Company before any distribution or payment shall be made to the holders of any common stock.

     

    The Series C Convertible Preferred Shares confer upon their holders the right to receive dividends when paid to holders of
      common stock of the Company on an as-converted basis. The shares  of Series C Convertible Preferred Stock have the right to receive a distribution of any surplus of assets upon liquidation of the Company before any distribution or payment shall be
      made to the holders of any other securities.

    

    

    Anti-Takeover Effects of the Company’s Articles and Bylaws

     

    Certain provisions of the Company’s Articles and Bylaws could have the effect of delaying, deterring or preventing another party from acquiring or
      seeking to acquire control of the Company. For example, the Company’s Articles and Bylaws include provisions that:

    

    

    	

          	•	
            allow the Board, subject to a majority vote of the entire Board, to amend the Company’s Bylaws at any meeting;

          

    

    

    	

          	•	
            provide that only stockholders owning thirty three and thirty four hundredths percent (33.34%) in amount of the entire capital stock of the Company’s issued and outstanding and entitled
              to vote may call a special meeting of the Company’s stockholders;

          

    

    

    	

          	•	
            the Board may from time to time increase or decrease the number of directors then comprising the Board, and may from time to time fill any vacancies, if any, on the Board; and

          

    

    

    	

          	•	
            empower the Board to issue from time to time one or more series of Preferred Stock, with such designations, rights, preferences and limitations as the Board may determine by resolution.
              The rights, preferences and limitations of separate series of Preferred Stock may differ with respect to such matters among such series of Preferred Stock as may be determined by the Board, including, without limitation, the rate of
              dividends, method and nature of payment of dividends, terms of redemption, amounts payable on liquidation, sinking fund provisions (if any), conversion rights (if any) and voting rights.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}]]